MedPath

Dexmedetomidine versus Haloperidol for Sedation of Non-intubated Patients with Hyperactive Delirium during the Night in a High Dependency Unit: an open-label, parallel-group, randomized controlled trial

Phase 4
Recruiting
Conditions
Hyperactive delirium
Registration Number
JPRN-jRCT1051220015
Lead Sponsor
Ohtsuru Shigeru
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Non-intubated patients who are urgently admitted to the High Dependency Unit of the Department of Primary Care and Emergency Medicine or the Department of Cardiovascular Medicine at Kyoto University Hospital from the emergency room.

Exclusion Criteria

Patients who have received non-invasive ventilation (NIV).
Patients with tracheostomy.
Patients who have already started to receive dexmedetomidine or haloperidol by bolus injection or drip infusion or intramuscular injection before admission to the High Dependency Unit.
Patients with a diagnosis of schizophrenia or mania.
Patients with contraindications to haloperidol or dexmedetomidine (e.g., allergy to any of the investigational drugs, prolonged QTc on electrocardiogram)
Women who are pregnant or possibly pregnant, and women who are lactating..
Patients who cannot understand Japanese
Other patients who are judged by the principal investigator or sub-investigator to be inappropriate for this study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of participants who achieve the targeted sedation level (RASS score of between -3 and 0) 2 hours after the start of administration of the investigational drug
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath